Tevogen Bio Holdings Inc. (“Company” or “Tevogen Bio”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T-cell therapeutics for ...

Koreas biotech firms strive for growth amid investment challenges at JP Morgan event K-Bio executives highlight new ...

Local biotech leaders are heading to San Francisco for the 2025 J.P. Morgan Healthcare Conference, one of the industry's biggest annual events. Hotels have been booked, the meetings scheduled and ...

The 43rd J.P. Morgan Healthcare Conference in San Francisco will see active participation by Korean pharmaceutical giants and up-and-comers, from featured presentations to deal making.

Samsung Biologics (KRX: 207940.KS), a global contract development and manufacturing organization (CDMO), today announced its latest business achievements and 2025 outlook at the 43rd J.P. Morgan ...

Korea’s top biopharmaceutical firms, Celltrion and Samsung Biologics, envisioned their future strategies for expansion at J.P ...

OraSure Technologies CEO Carrie Eglinton Manner said in her presentation that the firm's recent $25 million acquisition of ...

In the fireside chat, Dr. Rhew described how AI-driven modeling and simulation are drastically reducing the time required to identify and develop drug candidates. He provided an example where a ...